Maxiflam

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxiflam

What Type of Medicine is Maxiflam?

Maxiflam is a pharmaceutical preparation classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its active component, Naproxen Sodium, belongs to the propionic acid derivative group. The drug is categorized under the Anatomical Therapeutic Chemical (ATC) classification system as an anti-inflammatory and anti-rheumatic product. Maxiflam is typically manufactured into oral dosage forms, such as tablets or capsules, designed for systemic distribution throughout the body.

Maxiflam Composition and General Therapeutic Purpose

Maxiflam is a single-active-ingredient product utilizing the synthetic compound Naproxen Sodium. This specific salt formulation is used for its solubility, which supports the onset of action following oral ingestion. The medicine's general therapeutic purpose is to provide relief by modulating the body’s inflammatory response, a function used for managing general aches and discomfort, such as muscle stiffness. Naproxen Sodium acts by inhibiting the production of prostaglandins, which are chemical mediators involved in signaling pain and contributing to swelling. This mechanism allows the medication to address both pain and inflammation, assisting in the management of associated discomfort and stiffness.

What side effects are possible with Maxiflam?

Possible Side Effects and Safety Information

The official safety documentation for Maxiflam, an NSAID, outlines its adverse event profile based on frequency and system-organ classification.

Adverse Reaction Scope

Category Entity/Classification
Common Adverse Reactions Dyspepsia, Nausea, Headache, Dizziness, Heartburn, Drowsiness
System-Organ Classes Gastrointestinal, Cardiovascular, Renal/Urinary, Hepatic

Serious Adverse Reactions and Key Regulatory Constraints

The regulatory profile highlights risks associated with the NSAID class, which are classified as serious adverse reactions that may occur without warning symptoms. These include fatal Gastrointestinal Events such as bleeding, ulceration, and perforation, as well as fatal Cardiovascular Thrombotic Events (Myocardial Infarction and Stroke). Other serious documented reactions include severe Anaphylactoid Reactions and Skin Reactions (e.g., Stevens-Johnson Syndrome).

Risk is documented to increase with the duration of use, and in certain populations, notably Older Adults, who are at a greater risk for serious gastrointestinal and cardiovascular events. Use is Contraindicated in the setting of peri-operative coronary artery bypass graft (CABG) surgery and is generally not recommended in patients with severe, uncontrolled heart failure. Furthermore, use is avoided in the third trimester of Pregnancy due to the risk of premature fetal ductus arteriosus closure.

Regulatory Safety Structure

The official safety information rigorously structures the understanding of Maxiflam's risk profile around major System-Organ-Class risks and explicit Serious Adverse Reactions. By defining frequency categories and noting increased risks with exposure duration and in specific populations (like older adults), regulatory documents establish a clear, documented framework for the medicine’s safety characteristics. This framework is further solidified by contraindications that explicitly prohibit use in certain high-risk medical contexts.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Maxiflam (Naproxen Sodium) is a serious event based on official regulatory labeling, and all suspected cases require immediate emergency medical attention. The official overdose profile is structured around the potential for systemic toxicity and the lack of a specific neutralizing agent.

Documented Manifestations and Severe Outcomes

Overdose presentations commonly affect the gastrointestinal and central nervous systems. Clinical signs include common manifestations such as nausea, vomiting, and epigastric pain, alongside CNS effects like drowsiness, dizziness, and the sensory finding of tinnitus (ringing in the ears).

Regulatory documents formally report several severe outcomes. These include life-threatening conditions such as acute renal failure and metabolic acidosis. Neurological toxicity can escalate to seizures or, in severe cases, coma. The potential for serious gastrointestinal outcomes, including perforation, is also documented. Regulatory sources note that elderly patients face an increased risk for severe gastrointestinal adverse events following overexposure.

Required Emergency Action

Regulatory guidance strictly requires that emergency services must be contacted immediately upon suspected overexposure. The medical management is solely symptomatic and supportive, as official prescribing information confirms that no specific antidote is known for Naproxen overdose. Procedural steps described in regulatory literature include the administration of activated charcoal and continuous monitoring of vital signs.

Therapeutic Uses of Maxiflam

Maxiflam (Naproxen Sodium) is used in situations involving certain distressing symptoms across domains where inflammation, pain, and fever create noticeable interference with daily stability. It generally offers supportive therapeutic benefit by helping to ease the overall symptom burden in conditions involving inflammatory or irritative processes.

The medication is relevant in conditions characterized by periods of heightened symptoms, commonly used to help with pain, inflammation, and stiffness linked to conditions like Rheumatoid Arthritis (RA), Osteoarthritis (OA), Ankylosing Spondylitis (AS), acute gouty arthritis, tendinitis, bursitis, and primary dysmenorrhea. Applied during phases when symptoms become more noticeable, it contributes to improved comfort.

“The medication is commonly used when short-term symptomatic assistance is needed for general aches, pains, and fever, and may help patients cope more steadily with symptom fluctuations.”

Maxiflam helps address symptom clusters that may become intense or disruptive, may assist with maintaining functional stability, and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: May provide supportive relief for Inflammatory Pain and Swelling

Regulatory References

  1. Relief of Signs and Symptoms of Inflammatory Conditions

Eligibility and Restrictions for Use

Who Can and Cannot Use Maxiflam?

The eligibility for Maxiflam (Naproxen Sodium) is strictly governed by regulatory criteria based on absolute contraindications and population-specific restrictions documented in official labeling.

Absolute Contraindications

Maxiflam is contraindicated and must not be used by patients with a known hypersensitivity to naproxen or other NSAIDs, including those with a history of aspirin-sensitive asthma. Use is also strictly prohibited for pain management in the setting of peri-operative Coronary Artery Bypass Graft (CABG) surgery. It is further contraindicated for pregnant women at 30 weeks gestation and later (third trimester).

Age and Comorbidity Restrictions

OTC use is generally limited to adults and adolescents 12 years and older. Older adults are a higher-risk population, requiring caution. The medicine is not recommended for patients with moderate to severe renal impairment (creatinine clearance < 30 mL/min) or those with active gastrointestinal bleeding. Use should be avoided in patients with severe heart failure or advanced renal disease. Additionally, Maxiflam is generally avoided while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Maxiflam (Naproxen Sodium) interactions primarily through pharmacodynamic reinforcement and pharmacokinetic clearance interference. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is formally contraindicated due to the significantly increased risk of serious adverse effects, including gastrointestinal (GI) bleeding.

Documented Interaction Patterns

Interacting Substance/Class Official Regulatory Outcome Interaction Type
Anticoagulants (e.g., Warfarin) Increased risk of serious bleeding Pharmacodynamic
Lithium, Methotrexate Increased serum concentration of co-administered drug Pharmacokinetic
ACE Inhibitors, Diuretics Diminished anti-hypertensive and natriuretic effect Pharmacodynamic
Mifepristone Must be separated by 8–12 days after administration Timing-based
Alcohol (Ethanol) Increased risk of GI bleeding Pharmacodynamic

Maxiflam's regulatory profile notes that it can raise the plasma levels of Lithium and Methotrexate by interfering with their renal clearance or tubular secretion. Furthermore, its use is contraindicated for peri-operative pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with Antacids or Food may cause a slight decrease in the rate of absorption. Specific caution is noted for co-use with ACE Inhibitors in the elderly or those with impaired renal function, which may lead to renal deterioration.

Mechanism of Action

The mechanism of Naproxen is defined by its influence on inflammatory, nociceptive, and thermoregulatory processes, acting across central and peripheral systems by modulating specific enzyme activity.

The drug's primary action is the reversible inhibition of Cyclooxygenase (COX) enzymes, targeting both the COX-1 and COX-2 forms. This inhibition prevents the initial molecular step in the arachidonic acid cascade, thereby suppressing the synthesis of prostaglandins, which are key chemical mediators.

This molecular blockade initiates a vital physiological cascade. Peripherally, the suppression of prostaglandins prevents the sensitization of nociceptors (peripheral pain receptors), thereby attenuating the amplification of nociceptive signals. Centrally, the drug acts in the hypothalamus to block PGE2 synthesis, which effectively resets the body's elevated thermoregulatory set-point. These coordinated actions contribute to modifying pathway overactivity, resulting in an altered physiological state within the targeted systems. The mechanism is specific to pathways reliant on prostaglandin signaling.

Dosage and Administration Information

Instruction Map: How to use Maxiflam

This map outlines the instructions for the use of Maxiflam (Naproxen Sodium).


Administration Scope

Route of administration: Oral (via immediate-release tablets, delayed-release tablets, extended-release tablets, or oral suspension).

Dosing schedule: For chronic conditions like Osteoarthritis, the typical total daily dose ranges from 500 mg to 1000 mg (Naproxen base). Maximum dosage may be increased to 1500 mg per day for limited periods. For acute symptom management, initial doses are higher, followed by a reduction to maintenance doses of 250 mg or 275 mg every 6 to 12 hours as needed.

Timing in relation to meals (if applicable): Maxiflam should be taken with a full glass of water. Ingestion is preferably carried out with or after food or milk to aid gastrointestinal tolerance.

Preparation requirements (if applicable): Oral suspension must be gently shaken before each use and measured with a calibrated device. Delayed-Release (DR) and Extended-Release (ER) tablets must be swallowed whole and must not be crushed, broken, or chewed.

Age-group administration rules: A lower daily dosage should be considered for older adults and patients with known hepatic or renal impairment. For the pediatric indication of Juvenile Idiopathic Arthritis, the recommended total daily dose is approximately 10 mg/kg of body weight given in two divided doses.


Instruction Classifications (High-Level)

Administration method type: Oral.

Frequency pattern: Twice daily for immediate-release maintenance; Once daily for extended-release forms.

Use-context constraints: Usage is limited to the lowest effective dosage for the shortest duration necessary to control symptoms.


Resulting Procedural Structure

Step sequence:

  • Confirm the approved dose and strength based on the condition being addressed.
  • Administer the dose orally, taking care to swallow DR/ER tablets whole.
  • Ingest the dose with a full glass of water, ideally alongside food.

Connection to the overall use protocol (2–4 sentences): The administration protocol is standardized across various dosage forms and frequencies to provide structured use for acute versus chronic conditions. This structure details the required handling of the medication (swallowing whole vs. using a measuring device) and necessary intake conditions (with food) to ensure the drug is administered as intended.

Recent Clinical Evidence

Research evidence / Overview of studies for Maxiflam

Evidence for use in Chronic Inflammatory Conditions

Research examined Maxiflam (Naproxen Sodium) for conditions associated with inflammation, such as Rheumatoid Arthritis (RA), Osteoarthritis (OA), and Ankylosing Spondylitis (AS), using Randomized Controlled Trials (RCTs) and observational data. Studies were designed to monitor changes in patient-reported outcomes over defined time intervals, exploring how outcomes related to physical discomfort and functional limitations evolved.

The findings from these trials describe patterns observed in the studies, particularly concerning patient-reported outcomes describing perceived discomfort in the joints and overall symptomatic status. Research so far indicates that studies recorded measurements of change in joint pain and stiffness in the observed populations during the study periods.

Evidence for use in Acute and Intermittent Pain

The research for acute or episodic pain, including Primary Dysmenorrhea (menstrual pain), Acute Gout, and general mild-to-moderate discomfort, includes single-dose, double-blind, placebo-controlled RCTs and systematic reviews. Researchers monitored outcomes related to physical discomfort by quantifying pain intensity reduction and evaluating the time to the initial report of symptom change.

Studies provided data showing patterns related to the time interval between administration and the initial recording of any symptom change. Findings suggest that studies reported measured differences in pain intensity scores over short follow-up periods, typically assessed over a few hours.

Research Gaps and Areas of Uncertainty

While the existing evidence provides context, limitations and research needs remain recognized:

  • Comparative evidence is lacking: Direct comparison studies against all available non-steroidal anti-inflammatory drugs (NSAIDs) for every approved indication are limited.
  • Long-term outcomes: Long-term outcomes are not fully established through controlled trials, as follow-up durations were limited in the primary efficacy studies. Observational data are available but are generally less certain than findings from structured, controlled RCTs.
  • Specific Subgroups: Data for certain specific groups, such as children under 12 years of age (outside of Polyarticular Juvenile Idiopathic Arthritis studies), remain insufficient for drawing broad conclusions.

Frequently Asked Questions (FAQ)

Common questions about Maxiflam (FAQ)

Q: What is the main difference between Maxiflam and regular pain relievers?

Maxiflam (Naproxen Sodium) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official information states that its action is described as relieving pain and reducing inflammation, which distinguishes it from certain other pain relievers that primarily relieve pain without significant anti-inflammatory effects.


Q: Why is Maxiflam only available by prescription in some places?

According to regulatory labeling, the difference between prescription (Rx) and over-the-counter (OTC) forms is based on dosage strength and duration of use. Prescription strengths are defined to allow for higher total daily doses and are used for longer-term management, which requires physician supervision.


Q: Do people take Maxiflam for back pain or just joint pain?

Official OTC indications describe Naproxen Sodium as being used for the temporary relief of minor aches and pains from various causes. These include common issues like backache and muscular aches, in addition to minor pain associated with arthritis and joint pain.


Q: Can Maxiflam be used for headaches or migraines?

The non-prescription version of Naproxen Sodium is indicated for the temporary relief of pain due to headache. Furthermore, official product information indicates that it is an active ingredient in some prescription combination products that are specifically intended for the acute treatment of migraine.


Q: How quickly does Maxiflam usually start working after taking it?

Studies on the sodium salt formulation indicate a more rapid onset of action compared to the base drug. Peak concentrations of the medicine in the blood are typically reached within 1 to 2 hours based on pharmacokinetic studies.


Q: What is the typical time frame that Maxiflam's effects last?

Official information regarding the drug's properties shows that the medicine has a long presence in the body. The elimination half-life of naproxen is described as ranging from 12 to 17 hours, a duration that is consistent with its authorized twice-daily dosing frequency.


Q: Are there any specific foods that should be avoided when taking Maxiflam?

Official drug labels do not list specific foods that must be avoided. However, they suggest intake with food or milk to aid gastrointestinal tolerance. This intake condition is noted to potentially lessen stomach irritation. Separately, warnings regarding alcohol use (ethanol) are explicitly noted due to an increased risk of serious gastrointestinal bleeding.


Q: Can Maxiflam affect sleep patterns?

Regulatory documents list central nervous system effects under the adverse reactions reported during use. Specifically, the drug has been associated with reports of drowsiness (somnolence), which can influence a person's state of alertness.


Q: Is Maxiflam described as a non-opioid pain reliever?

Yes. Regulatory and official classifications define Maxiflam (Naproxen Sodium) as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification confirms that the medicine is not part of the opioid class of pain relievers.


Q: How does the mechanism of action of Maxiflam differ from Tylenol (acetaminophen)?

The mechanism of action for Maxiflam involves inhibiting specific enzymes to reduce both pain and inflammation throughout the body. Regulatory-sourced information indicates that unlike NSAIDs, drugs like acetaminophen work primarily within the central nervous system to reduce pain and fever, and generally do not target inflammation.


Q: Is Maxiflam generally recommended for short-term or long-term pain management?

Official labeling supports the use of Maxiflam for both short-term management of acute pain and long-term use for chronic conditions. Official labeling emphasizes that the medicine should be used at the lowest effective dose for the shortest duration of time.


Q: What is the maximum amount of time Maxiflam is usually prescribed for?

For OTC use, the label states the drug should generally be used for no more than 10 days without medical consultation. For certain chronic conditions under supervision, official labeling notes that the maximum daily dose may be used for limited periods, up to 6 months.


Q: Are generic versions of Maxiflam considered equivalent by regulatory agencies?

Yes. Regulatory agencies like the FDA approve generic versions of Naproxen Sodium. These generic products are often noted in official documents as being bioequivalent to the brand-name formulation, meaning they contain the same active ingredient and work the same way in the body.


Q: Is it normal to have mild water retention when taking Maxiflam?

Official warnings note that drugs in this class can cause fluid retention, or edema. Swelling, particularly of the face, fingers, feet, or lower legs, is listed in the official safety profile as a potential sign that warrants awareness.


Q: Have there been changes in the official warnings for Maxiflam in recent years?

Yes. Official prescribing documents are required to track label changes. These documents include a specific section titled RECENT MAJOR CHANGES which records all regulatory revisions made to the drug’s warnings, precautions, and indications.


Q: Is Maxiflam generally safe during breastfeeding?

Regulatory information indicates that Naproxen is known to pass into breast milk. Because of this, the decision regarding continuing the drug or discontinuing breastfeeding is defined in regulatory documents as a medical determination.

How should Maxiflam be stored and disposed of?

How to Store and Dispose of Maxiflam (Naproxen Sodium)

Official regulatory guidelines define specific conditions for storing and discarding Maxiflam to maintain its stability and ensure safety.

Storage Requirements

Maxiflam (Naproxen Sodium) tablets and capsules must be stored at Controlled Room Temperature (typically 20 C to 25 C). The medicine must be kept out of the sight and reach of children at all times. It is required to keep the product in its original, tightly closed container and protect it from both light and excessive moisture or heat. Freezing of the product must be avoided.

Disposal Instructions

Unused or expired Maxiflam must be disposed of in accordance with local requirements to prevent environmental contamination. The official guidance recommends utilizing an established drug take-back program where available. If no program is accessible, the medicine should be mixed with an unappealing substance, placed in a sealed container, and discarded in the household trash. The product should not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maxiflam found in:

A-Z Index: